| Phase 1/21 trial · 1 met primary |
|
Phase 1/2
|
NCT02743897 |
May 2016 → Mar 2022 |
end stage renal failure |
University of Pennsylvania |
Completed
|
Met primary
|
| Phase 21 trial |
|
Phase 2
|
NCT03523871 |
May 2018 → Sep 2020 |
hepatitis C virus infection |
NYU Langone Health |
Completed
|
No outcome recorded
|
| Phase 44 trials |
|
Phase 4
|
NCT04508907 |
Sep 2020 → Nov 2025 overdue |
disease related to solid organ transplantation, hepatitis C virus infection |
Mayo Clinic |
Active not recruiting
|
No outcome recorded
|
|
Phase 4
|
NCT03625687 |
Feb 2019 → Apr 2022 |
hepatitis C virus infection, respiratory failure |
Massachusetts General Hospital |
Terminated
|
No outcome recorded
Stop: Business |
|
Phase 4
|
NCT03382847 |
Jan 2018 → May 2020 |
heart failure |
NYU Langone Health |
Completed
|
No outcome recorded
|
|
Phase 4
|
NCT02946034 |
Feb 2017 → Sep 2020 |
chronic hepatitis C virus infection, chronic kidney disease |
Massachusetts General Hospital |
Completed
|
No outcome recorded
|
| Phase not applicable1 trial |
| — |
NCT05108935 |
Feb 2022 → Mar 2023 |
HIV infectious disease, hepatitis C virus infection, opiate dependence |
Duke University |
Completed
|
No outcome recorded
|